Fibrillary Glomerulonephritis in Rheumatoid Arthritis

Yun, Yu-Seon; Song, Ho Cheol; Lee, Kyungji; Choi, Euy Jin; Kim, Yong Soo; Min, Jun‐Ki; Kim, Yong Kyun

doi:10.1111/j.1440-1797.2009.01164.x

Cited by 10 publications

(1 citation statement)

References 3 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Deposition of mesangial IgA correlated with the duration of RA and elevated serum IgA levels, whereas mesangial IgM deposition was correlated with serum levels of IgM class RF [138]. In addition, single reports reveal the presence of FSGS [139] and fibrillary glomerulonephritis [140] in RA patients. Anti-TNF alpha therapy can be causative for the development of necrotizing crescentic glomerulonephritis and proliferative lupus nephritis [141,142].…”

Section: Reviewmentioning

confidence: 99%

Renal involvement in autoimmune connective tissue diseases

Kronbichler

Mayer

2013

BMC Med

105

View full text Add to dashboard Cite

Connective tissue diseases (CTDs) are a heterogeneous group of disorders that share certain clinical presentations and a disturbed immunoregulation, leading to autoantibody production. Subclinical or overt renal manifestations are frequently observed and complicate the clinical course of CTDs. Alterations of kidney function in Sjögren syndrome, systemic scleroderma (SSc), auto-immune myopathies (dermatomyositis and polymyositis), systemic lupus erythematosus (SLE), antiphospholipid syndrome nephropathy (APSN) as well as rheumatoid arthritis (RA) are frequently present and physicians should be aware of that.In SLE, renal prognosis significantly improved based on specific classification and treatment strategies adjusted to kidney biopsy findings. Patients with scleroderma renal crisis (SRC), which is usually characterized by severe hypertension, progressive decline of renal function and thrombotic microangiopathy, show a significant benefit of early angiotensin-converting-enzyme (ACE) inhibitor use in particular and strict blood pressure control in general. Treatment of the underlying autoimmune disorder or discontinuation of specific therapeutic agents improves kidney function in most patients with Sjögren syndrome, auto-immune myopathies, APSN and RA.In this review we focus on impairment of renal function in relation to underlying disease or adverse drug effects and implications on treatment decisions.

show abstract